Valuation check: RADLY's P/E ratio is 25.11, below the Healthcare sector average of 27.28.
Get informed when a big investor buys or sells
+ Follow25.11
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Raia Drogasil S.A.'s p/e ratio stands at 25.11. That is below the Healthcare sector average of 27.28. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Raia Drogasil S.A. sits lower the Healthcare benchmark (27.28) with a P/E ratio of 25.11. That is roughly 7.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 25.11 is attractive depends on Raia Drogasil S.A.'s earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Raia Drogasil S.A.'s P/E ratio evolved across reporting periods, while the comparison chart places RADLY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Raia Drogasil S.A.'s reading of 25.11 (sector avg 27.28) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.